The European Medicines Agency has validated its marketing authorization application for repotrectinib in adult patients with ROS1 TKI-naive or -pretreated locally advanced or metastatic non–small cell lung cancer harboring ROS1 fusions, as well as adult and pediatric patients with TKI-naive and pretreated NTRK-positive locally advanced or metastatic solid tumors.
Explore safe travel tips for cancer patients, including when not to travel, potential risks, and how to prepare for a trip. Learn about medical travel agencies and travel health specialists.
About the Office of Education and Training fredhutch.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fredhutch.org Daily Mail and Mail on Sunday newspapers.
China’s National Medical Products Administration has approved durvalumab plus gemcitabine and cisplatin for frontline use in adult patients with locally advanced or metastatic biliary tract cancer.
After a re-examination procedure, the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion on the conditional marketing authorization application for adagrasib in the treatment of adult patients with KRAS G12C–mutated advanced non–small cell lung cancer whose disease progressed following at least 1 prior systemic treatment.